Citi raised the firm’s price target on Sotera Health (SHC) to $20 from $18 and keeps a Buy rating on the shares. The firm cites the “solid” Q3 results for the target increase. It remains constructive on Sotera’s long-term opportunity while acknowledging the potential risks associated with the litigation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health price target raised to $18 from $17 at Barclays
- Sotera Health Reports Strong Q3 2024 Performance
- Sotera Health reports Q3 adjusted EPS 17c, consensus 18c
- Sotera Health reaffirms FY24 adjusted EPS view 67c-75c, consensus 72c
- SHC Earnings Report this Week: Is It a Buy, Ahead of Earnings?